{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(2)"],"submitter":["Barca-Hernando M"],"pubmed_abstract":["<h4>Background</h4>Clinical guidelines suggest continuing anticoagulation therapy for >6 months for patients with active cancer and venous thromboembolism (VTE). However, data regarding the safety of its discontinuation are scarce.<h4>Objectives</h4>To valuate the risk factors and the incidence of recurrent VTE 6 months after the discontinuation of anticoagulation therapy in patients with cancer-associated thrombosis (CAT).<h4>Methods</h4>We performed a retrospective study on consecutive patients with CAT recruited between 2008 and 2019. The primary and secondary outcomes were recurrent VTE at 6 and 12 months, respectively. Sensitivity analyses were conducted to investigate the possible heterogeneity of these effects.<h4>Results</h4>A total of 311 patients were included, among whom 33.4% h"],"journal":["Research and practice in thrombosis and haemostasis"],"pagination":["100115"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10099299"],"repository":["biostudies-literature"],"pubmed_title":["Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy."],"pmcid":["PMC10099299"],"pubmed_authors":["Carrier M","Barca-Hernando M","Garcia-Garcia V","Elias-Hernandez T","Otero-Candelera R","Marin-Romero S","Jara-Palomares L","Lopez-Ruz S"],"additional_accession":[]},"is_claimable":false,"name":"Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy.","description":"<h4>Background</h4>Clinical guidelines suggest continuing anticoagulation therapy for >6 months for patients with active cancer and venous thromboembolism (VTE). However, data regarding the safety of its discontinuation are scarce.<h4>Objectives</h4>To valuate the risk factors and the incidence of recurrent VTE 6 months after the discontinuation of anticoagulation therapy in patients with cancer-associated thrombosis (CAT).<h4>Methods</h4>We performed a retrospective study on consecutive patients with CAT recruited between 2008 and 2019. The primary and secondary outcomes were recurrent VTE at 6 and 12 months, respectively. Sensitivity analyses were conducted to investigate the possible heterogeneity of these effects.<h4>Results</h4>A total of 311 patients were included, among whom 33.4% h","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-04T07:11:19.518Z","creation":"2025-04-04T07:11:19.518Z"},"accession":"S-EPMC10099299","cross_references":{"pubmed":["37063761"],"doi":["10.1016/j.rpth.2023.100115"]}}